Clinical Trial Update: A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients [Phase 3]

View source ↗

Summary

An update on a Phase 3 study evaluating oral sudapyridine (WX-081) for rifampin-resistant pulmonary tuberculosis and multidrug-resistant tuberculosis, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Rifampin-resistant Pulmonary Tuberculosis
• Tuberculosis

Drugs mentioned

• Sudapyridine (WX-081) (sudapyridine)

Snippet

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd | Conditions: Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB) | Phase 3 | Status: RECRUITING